-
EP2088991
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2088991
| EP2088991 - USE OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL]HEXANE FOR THE PREPARATION OF COSMETIC COMPOSITIONS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 15.07.2011 Database last updated on 11.05.2024 | Most recent event Tooltip | 15.07.2011 | Application deemed to be withdrawn | published on 17.08.2011 [2011/33] | Applicant(s) | For all designated states Revotar Biopharmaceuticals AG Neuendorfstrasse 24a 16761 Henningsdorf / DE | [2009/34] | Inventor(s) | 01 /
AYDT, Ewald, M. Schulgasse 53 64380 Roßdorf / DE | 02 /
BOCK, Daniel Weissenburgstr. 8 30161 Hannover / DE | 03 /
VOLLHARDT, Karin Am Eichenhain 16 16761 Hennigsdorf / DE | 04 /
WOLFF, Gerhard 69F New England Avenue Summit, 07901 NJ / US | [2010/04] |
| Former [2009/46] | 01 /
AYDT, Ewald, M. Schulgasse 53 64380 Roßdorf / DE | ||
| 02 /
BOCK, Daniel Weissenburgstr. 8 30161 Hannover / DE | |||
| 03 /
VOLLHARDT, Karin Am Eichenhain 16 16761 Hennigsdorf / DE | |||
| 04 /
WOLFF, Gerhard 312 Garfield Place Brooklyn, 11215 NY / US | |||
| Former [2009/34] | 01 /
AYDT, Ewald, M. Lloyd-G.-Wells-Strasse 20 14163 Berlin / DE | ||
| 02 /
BOCK, Daniel Weissenburgstr. 8 30161 Hannover / DE | |||
| 03 /
VOLLHARDT, Karin Am Eichenhain 16 16761 Hennigsdorf / DE | |||
| 04 /
WOLFF, Gerhard 312 Garfield Place Brooklyn, 11215 NY / US | Representative(s) | Jacobi, Markus Alexander Patentanwälte Isenbruck Bösl Hörschler PartG mbB Eastsite One Seckenheimer Landstrasse 4 68163 Mannheim / DE | [N/P] |
| Former [2009/34] | Jacobi, Markus Alexander Isenbruck Bösl Hörschler Wichmann Huhn LLP Patentanwälte Eastsite One Seckenheimer Landstrasse 4 68163 Mannheim / DE | Application number, filing date | 07803327.1 | 07.09.2007 | [2009/34] | WO2007EP59382 | Priority number, date | EP20060120400 | 08.09.2006 Original published format: EP 06120400 | [2009/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2008028950 | Date: | 13.03.2008 | Language: | EN | [2008/11] | Type: | A1 Application with search report | No.: | EP2088991 | Date: | 19.08.2009 | Language: | EN | The application published by WIPO in one of the EPO official languages on 13.03.2008 takes the place of the publication of the European patent application. | [2009/34] | Search report(s) | International search report - published on: | EP | 13.03.2008 | Classification | IPC: | A61K8/60, A61Q19/08, A61Q19/00, A61Q17/00 | [2009/34] | CPC: |
A61Q19/08 (EP,US);
A61K8/498 (EP,US);
A61K8/602 (EP,US);
A61P17/00 (EP);
A61Q17/00 (EP,US);
A61Q19/00 (EP,US)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2009/34] | Title | German: | VERWENDUNG VON 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL]HEXAN ZUR HERSTELLUNG VON KOSMETISCHEN ZUSAMMENSETZUNGEN | [2009/34] | English: | USE OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL]HEXANE FOR THE PREPARATION OF COSMETIC COMPOSITIONS | [2009/34] | French: | UTILISATION DU 1,6-BISÝ3-(3-CARBOXYMÉTHYLPHÉNYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHÉNYL ̈HEXANE POUR LA PRÉPARATION DE COMPOSITIONS COSMÉTIQUES | [2009/34] | Entry into regional phase | 07.04.2009 | National basic fee paid | 07.04.2009 | Designation fee(s) paid | 07.04.2009 | Examination fee paid | Examination procedure | 07.04.2009 | Examination requested [2009/34] | 29.07.2010 | Despatch of a communication from the examining division (Time limit: M06) | 09.02.2011 | Application deemed to be withdrawn, date of legal effect [2011/33] | 17.03.2011 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2011/33] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 29.07.2010 | Fees paid | Renewal fee | 28.09.2009 | Renewal fee patent year 03 | 28.09.2010 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [DX]WO9701335 (TEXAS BIOTECHNOLOGY CORP [US], et al) [DX] 9,10 * page 7; compound A * * page 11, line 28 - page 14, line 18; examples 1,10; claim - *; | [X] - PHILIPP S ET AL, "Demonstration of antipsoriatic efficacy of a new topical formulation of a small molecule selectin antagonist bimosiamose", JOURNAL OF INVESTIGATIVE DERMATOLOGY, 66TH ANNUAL MEETING OF THE SOCIETY-FOR-INVESTIGATIVE-DERMATOLOGY; ST LOUIS, MO, USA; MAY 04 -07, 2005, (200504), vol. 124, no. 4, Suppl. S, ISSN 0022-202X, page A38, XP002418882 [X] 1-10 * abstract 228 * DOI: http://dx.doi.org/10.1111/j.0022-202X.2004.23539.x | [X] - PHILIPP S ET AL, "Demonstration of antipsoriatic efficacy of a new topical formulation of a small molecule selectin antagonist bimosiamose", JOURNAL OF INVESTIGATIVE DERMATOLOGY, 35TH ANNUAL MEETING OF THE EUROPEAN-SOCIETY-FOR-DERMATOLOGICAL-RESEA RCH; TUBINGEN, GERMANY; SEPTEMBER 22 -24, 2005, (200509), vol. 125, no. 3, Suppl. S, ISSN 0022-202X, page A34, XP002418883 [X] 1-10 * abstract 197 * DOI: http://dx.doi.org/10.1111/j.0022-202X.2005.23763.x | [X] - MEALY N.E. ET AL, "Annual update 2003/2004- treatment of dermatological disorders", DRUGS OF THE FUTURE , 29(4), 393-436 CODEN: DRFUD4; ISSN: 0377-8282, (2004), XP002418884 [X] 1-10 * page 407 * | [X] - FRIEDRICH M ET AL, "Bimosiamose, a pan-selectin antagonist improves disease manifestation both in human psoriatic skin SCID mice and psoriatic patients: Selectin antagonists as a new treatment strategy for inflammatory diseases.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, INTERNATIONAL INVESTIGATIVE DERMATOLOGY 2003 : JOINT MEETING OF THE EUROPEAN SOCIETY FOR DERMATOLOGI; MIAMI BEACH, FLORIDA, USA; APRIL 30-MAY 04, 2003, (200307), vol. 121, no. 1, ISSN 0022-202X, page 0367, XP002418885 [X] 1-10 * abstract * DOI: http://dx.doi.org/10.1046/j.1523-1747.2003.12482.x | [X] - MARKUS FRIEDRICH ET AL, "Pan-selectin antagonism improves psoriasis manifestation in mice and man", ARCHIVES OF DERMATOLOGICAL RESEARCH ; FOUNDED IN 1869 AS ARCHIV FÜR DERMATOLOGIE UND SYPHILIS, SPRINGER-VERLAG, BE, (20060201), vol. 297, no. 8, ISSN 1432-069X, pages 345 - 351, XP019341197 [X] 1-10 * the whole document * DOI: http://dx.doi.org/10.1007/s00403-005-0626-0 | [X] - "Press Release: First Positive Results With a New Topical Formulation of Bimosiamose in Psoriasis, will be presented at the European Congress of Psoriasis", (20041115), URL: HTTP://WWW.REVOTAR.DE/PDF/TOPICAL_PRESS_RELEASE_PARIS.PDF, (20070207), XP002418886 [X] 1-10 * the whole document * | [X] - "First Positive Results With a New Topical Formulation of Bimosiamose in Psoriasis, will be presented at the European Congress of Psoriasis", (20041021), URL: HTTP://WWW.BIOTOP.DE/NEWS/ARCHIV_DETAIL_E.ASP?QUICKSEARCH=&ABSOLUTEPAGE=11&ID=1294, (20070207), XP002418887 [X] 1-10 * the whole document * | [X] - "Texas Biotechnology and Revotar Pharmaceuticals AG Initiate Phase I Study with Novel Selectin Antagonist, TBC 1269", (20010626), URL: HTTP://IR.ENCYSIVE.COM/IREYE/IR_SITE.ZHTML?TICKER=ENCY&SCRIPT=460&LAYOUT=-6&ITEM_ID=236633, (20070207), XP002418888 [X] 1-10 * the whole document * |